Difference between revisions of "Aripiprazole LA-Clozapine"

From Psychiatrienet
Jump to: navigation, search
(hoofdletter...)
(One intermediate revision by one other user not shown)
Line 1: Line 1:
 
{{Drugswitch  
 
{{Drugswitch  
 
| from = Aripiprazole LA
 
| from = Aripiprazole LA
| to = clozapine
+
| to = Clozapine
 
| stop = {{Lastinjection}}
 
| stop = {{Lastinjection}}
 
| start =  
 
| start =  
 
* '''Day 3:''' Start with 12,5 mg
 
* '''Day 3:''' Start with 12,5 mg
* '''Next weeks: ''' increase with step of 25 mg
+
* '''Next weeks: ''' increase with steps of 25 mg
 
{{Startslweeks}}
 
{{Startslweeks}}
 
| info = {{SPCaripiprazoleLA}}
 
| info = {{SPCaripiprazoleLA}}
 
| view = StopDepotStartOral.jpg
 
| view = StopDepotStartOral.jpg
 
}}
 
}}

Revision as of 14:46, 20 March 2015

Aripiprazole
long acting
Type Antipsychotic
Group Atypical AP
Other use moodstabilizer
links
Medscape Aripiprazole
EMEA abilify
PubChem 60975
PubMed Aripiprazole
Kompas (Dutch) Aripiprazole
Wikipedia Aripiprazole
Clozapine
Type Antipsychotic
Group Atypical AP
links
Medscape Clozapine
PubChem 2818
PubMed Clozapine
Kompas (Dutch) Clozapine
Wikipedia Clozapine

Switch medication from Aripiprazole LA to Clozapine.[1] [2]

Nietinrijdenbord.png Stop Aripiprazole LA
  • Day 1: Last depot injection
Eenrichtingbord.png Start Clozapine
  • Day 3: Start with 12,5 mg
  • Next weeks: increase with steps of 25 mg
  • Week 1-3: approx. 25% of target dose
  • Week 4-6: approx. 50% of target dose
  • Week 7-9: approx. 75% of target dose
  • Week 10: target dose
Infobord.png More information
  • More information you'll find in the summary of product characteristics (SPC) of aripiprazole depot injection. [3]
    StopDepotStartOral.jpg
Nietinrijdenbord.png — Aripiprazole LA
Eenrichtingbord.png — Clozapine


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002755/WC500156111.pdf SPC of the European Medicines Agency on aripiprazole depot
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.